These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22951705)

  • 1. Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: a review.
    Intiso D; Basciani M
    NeuroRehabilitation; 2012; 31(2):117-29. PubMed ID: 22951705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Botulinum toxin therapy for spasticity].
    Masakado Y
    Brain Nerve; 2014 Sep; 66(9):1039-47. PubMed ID: 25200575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Spasticity must be treated by botulinum toxin with rehabilitaiton].
    Masakado Y
    Rinsho Shinkeigaku; 2013; 23(11):1261-3. PubMed ID: 24291950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B for sialorrhea in children with cerebral palsy.
    Reddihough D; Graham HK
    Dev Med Child Neurol; 2011 Jun; 53(6):488-9. PubMed ID: 21501158
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
    Wilken B; Aslami B; Backes H
    Neuropediatrics; 2008 Aug; 39(4):200-4. PubMed ID: 19165707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of botulinum toxic injection to treat excessive drooling in children with neurological conditions.
    Khan A; Pawar G
    W V Med J; 2005; 101(6):258-60. PubMed ID: 16625812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
    Contarino MF; Pompili M; Tittoto P; Vanacore N; Sabatelli M; Cedrone A; Rapaccini GL; Gasbarrini G; Tonali PA; Bentivoglio AR
    Parkinsonism Relat Disord; 2007 Jul; 13(5):299-303. PubMed ID: 16807056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment.
    Russman BS; Tilton A; Gormley ME
    Muscle Nerve Suppl; 1997; 6():S181-93. PubMed ID: 9826990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Children undergoing treatment with botulinum toxin: the role of the physical therapist.
    Leach J
    Muscle Nerve Suppl; 1997; 6():S194-207. PubMed ID: 9826991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic use of botulinum toxin in neurorehabilitation.
    Intiso D
    J Toxicol; 2012; 2012():802893. PubMed ID: 21941544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review.
    Porte M; Chaléat-Valayer E; Patte K; D'Anjou MC; Boulay C; Laffont I
    Eur J Paediatr Neurol; 2014 Nov; 18(6):649-57. PubMed ID: 24931915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses.
    Basciani M; Di Rienzo F; Fontana A; Copetti M; Pellegrini F; Intiso D
    Dev Med Child Neurol; 2011 Jun; 53(6):559-64. PubMed ID: 21413974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis.
    Verma A; Steele J
    Muscle Nerve; 2006 Aug; 34(2):235-7. PubMed ID: 16583370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence.
    Schroeder AS; Kling T; Huss K; Borggraefe I; Koerte IK; Blaschek A; Jahn K; Heinen F; Berweck S
    Neuropediatrics; 2012 Feb; 43(1):27-36. PubMed ID: 22430158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic indications for botulinum toxins.
    Cordivari C; Misra VP; Catania S; Lees AJ
    Mov Disord; 2004 Mar; 19 Suppl 8():S157-61. PubMed ID: 15027069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders.
    Yablon SA
    Phys Med Rehabil Clin N Am; 2001 Nov; 12(4):833-74, vii-viii. PubMed ID: 11723867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
    Heinen F; Desloovere K; Schroeder AS; Berweck S; Borggraefe I; van Campenhout A; Andersen GL; Aydin R; Becher JG; Bernert G; Caballero IM; Carr L; Valayer EC; Desiato MT; Fairhurst C; Filipetti P; Hassink RI; Hustedt U; Jozwiak M; Kocer SI; Kolanowski E; Krägeloh-Mann I; Kutlay S; Mäenpää H; Mall V; McArthur P; Morel E; Papavassiliou A; Pascual-Pascual I; Pedersen SA; Plasschaert FS; van der Ploeg I; Remy-Neris O; Renders A; Di Rosa G; Steinlin M; Tedroff K; Valls JV; Viehweger E; Molenaers G
    Eur J Paediatr Neurol; 2010 Jan; 14(1):45-66. PubMed ID: 19914110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.
    Alrefai AH; Aburahma SK; Khader YS
    Clin Neurol Neurosurg; 2009 Jan; 111(1):79-82. PubMed ID: 18977585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
    Tan EK
    Eur J Neurol; 2006 Feb; 13 Suppl 1():60-4. PubMed ID: 16417600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin as an effective treatment of clozapine-induced hypersalivation.
    Kahl KG; Hagenah J; Zapf S; Trillenberg P; Klein C; Lencer R
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):229-30. PubMed ID: 14747903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.